Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Añadir filtros








Intervalo de año
1.
Indian J Pediatr ; 2005 Oct; 72(10): 881-2
Artículo en Inglés | IMSEAR | ID: sea-83195

RESUMEN

A 40-day-old male child was admitted with complaints of not opening eyes from 2-3 days after birth. A diagnosis of X3-B keratomalacia was made. The treatment was done with vitamin-A to which the patient had responded. The mother of the baby had a history of night blindness throughout the pregnancy for which she was also treated. Keratomalacia secondary to vitamin-A deficiency is rare in neonates, although in children it is reported form developing countries.


Asunto(s)
Adulto , Factores de Edad , Enfermedades de la Córnea/tratamiento farmacológico , Opacidad de la Córnea/etiología , Úlcera de la Córnea/tratamiento farmacológico , Femenino , Humanos , Lactante , Masculino , Ceguera Nocturna/tratamiento farmacológico , Fotofobia/etiología , Embarazo , Complicaciones del Embarazo , Factores de Tiempo , Resultado del Tratamiento , Vitamina A/administración & dosificación , Deficiencia de Vitamina A/tratamiento farmacológico
2.
J Indian Med Assoc ; 1999 Aug; 97(8): 320-3
Artículo en Inglés | IMSEAR | ID: sea-99589

RESUMEN

The major cause of blindness in children worldwide is xerophthalmia caused by vitamin A deficiency. In addition it has other adverse effects, including increased mortality and the term vitamin A deficiency disorders (VADD) has been introduced to cover the whole clinical spectrum of disease. The ocular manifestations of xerophthalmia have been classified and a set of prevalence criteria for the detection of a problem of public health magnitude has been in use for more than two decades. The global prevalence of VADD is now well documented and World Health Organisation (WHO) receives information continuously for updating its data base on the subject. The pathogenesis of the disease is still imperfectly understood, it is not at all clear precisely why certain subjects in vulnerable communities develop xerophthalmia, while the majority are spared. A schedule for treatment of the established case has been available for a long time, but at both clinic and hospital level concentrated sources of vitamin A for treatment are frequently not available. More emphasis needs to be laid on prevention and a choice of methods consisting of large dose supplementation, fortification of food, control of precipitating infections and dietary improvement. The advantages and drawbacks of each are discussed.


Asunto(s)
Adulto , Factores de Edad , Niño , Enfermedades de la Córnea/etiología , Humanos , India/epidemiología , Ceguera Nocturna/tratamiento farmacológico , Prevalencia , Vitamina A/administración & dosificación , Deficiencia de Vitamina A/complicaciones , Organización Mundial de la Salud , Xeroftalmia/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA